within Pharmacolibrary.Drugs.ATC.J;

model J04AK08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.53,
    Cl             = 0.00026,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.18,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 10.020000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J04AK08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pretomanid is a nitroimidazooxazine-class antibacterial drug used as part of combination therapy for the treatment of extensively drug-resistant, treatment-intolerant or non-responsive multidrug-resistant pulmonary tuberculosis in adults. It is approved by the US FDA (2019) and EMA as a component of specific multidrug regimens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration, fasted or fed conditions, both sexes.</p><h4>References</h4><ol><li><p>Lyons, MA (2018). Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients. <i>Antimicrobial agents and chemotherapy</i> 62(7) –. DOI:<a href=\"https://doi.org/10.1128/AAC.02359-17\">10.1128/AAC.02359-17</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29661865/\">https://pubmed.ncbi.nlm.nih.gov/29661865</a></p></li><li><p>Rodvold, KA, Gotfried, MH, Ussery, XT, Wong, SL, &amp; Hamed, KA (2024). Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers. <i>Antimicrobial agents and chemotherapy</i> 68(11) e0110324–None. DOI:<a href=\"https://doi.org/10.1128/aac.01103-24\">10.1128/aac.01103-24</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39352135/\">https://pubmed.ncbi.nlm.nih.gov/39352135</a></p></li><li><p>Sun, Q, Li, S, Gao, M, &amp; Pang, Y (2024). Therapeutic Strategies for Tuberculosis: Progress and Lessons Learned. <i>Biomedical and environmental sciences : BES</i> 37(11) 1310–1323. DOI:<a href=\"https://doi.org/10.3967/bes2024.168\">10.3967/bes2024.168</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39667968/\">https://pubmed.ncbi.nlm.nih.gov/39667968</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J04AK08;
